Calling for Urgent Adoption of Lenacapavir in PrEP Guidelines: A Step Forward in HIV Prevention

By

Lenacapavir represents a major advance in HIV prevention. As a capsid inhibitor, it interrupts multiple stages of the HIV lifecycle, making it distinct from other treatments. This long-acting injectable has shown remarkable efficacy in blocking HIV replication, making it a promising option for both prevention and treatment, particularly in heavily treatment-experienced adults with multi-drug-resistant HIV.

The introduction of Lenacapavir is a game-changer, offering new hope to millions affected by HIV, especially in high-incidence, resource-limited countries. With Gilead’s recent voluntary licensing agreements, six generic manufacturers have been empowered to produce and supply Lenacapavir at low cost. This decision to roll out Lenacapavir through partnerships in 120 countries, including Botswana, South Africa, and Kenya, underscores Gilead’s commitment to global health equity. By offering the drug at no profit until generic manufacturers can meet demand, Gilead has set a new benchmark in access to life-saving medications.

It is now imperative for high-burden countries in our region to adapt their national PrEP guidelines to include Lenacapavir. With its transformative potential, Lenacapavir could significantly enhance our HIV prevention strategies, reducing new infections and providing a more sustainable prevention method than daily oral PrEP regimens. National health authorities should begin aligning their PrEP guidelines to fast-track access once regulatory approvals are finalized.

To this end, Ministries of Health (MoH) in beneficiary countries must convene their PrEP Technical Working Groups (TWGs) urgently and begin the process of updating PrEP guidelines to include Lenacapavir. The TWGs should avoid long, protracted meetings that slow progress, given the pressing need for rapid action. Every delay in updating these guidelines could result in missed opportunities to prevent new infections in communities that need these interventions most.

Additionally, Lenacapavir's application in HIV treatment for those with multi-drug resistance offers new hope for a population that has historically had few options. Its unique action mechanism allows it to overcome resistance where other drugs have failed, making it a critical part of the HIV treatment arsenal.

In conclusion, I extend my deepest gratitude to Gilead for their visionary approach to making Lenacapavir accessible. Their bold move will undoubtedly have a profound impact on HIV prevention, particularly in regions where resources are limited and the need for effective intervention is most urgent. By embracing Lenacapavir, we move one step closer to a future where HIV is no longer a major public health threat, and we owe it to our communities to seize this moment and act with urgency.

Kennedy Mupeli

Welcome to my blog dedicated to community engagement in HIV research. Here, we delve deep into the latest advancements and discussions surrounding HIV cure, treatment, prevention, and management of advanced HIV infection. My goal is to bridge the gap between complex scientific research and community understanding, ensuring that knowledge is accessible and actionable. Join me as I explore these critical topics, engage with community insights, and contribute to the ongoing fight against HIV.

Comments

Post a Comment

Popular posts from this blog

Aging with HIV in Botswana: Time to Update Our Treatment Guidelines

By
A New Face of Botswana’s HIV Epidemic As an HIV activist, I have witnessed a profound shift in our epidemic’s demographics. Two decades ago, the focus was on keeping people alive. Today, thanks to widespread antiretroviral therapy (ART), many of those same people are alive into their 50s, 60s, and beyond. In fact, Botswana’s HIV population is graying rapidly. By some estimates, over 50% of people living with HIV in Botswana are now over 40 years old, making older adults the new face of our country’s HIV community. This is a testament to our success in expanding treatment, but it also presents urgent new challenges. While ART has extended life expectancy, additional years of life are not necessarily spent in good health. Many older PLHIV are surviving, but not thriving. They struggle with chronic pain, fatigue, heart disease, or depression. Such stories underscore a hard truth: we have won on longevity, but we are lagging on quality of life. Medical complications, multimorbidities, ...
Read more

HIV Prevention Research in a Time of Scarcity: Why Health Economics Must Lead the Way

By
What is Health Economics? Health economics is a field of study that examines how health resources are allocated, used, and financed. It helps decision-makers understand the trade-offs involved in investing in different health interventions by analysing their costs, benefits, and overall impact on population health. Through tools such as cost-effectiveness analysis and budget impact modelling, health economics supports evidence-based decisions that aim to maximise health outcomes with limited resources. In HIV prevention, this means ensuring that every intervention, from new biomedical tools to health service delivery, delivers real value for money and is accessible to the people who need it most. Why Health Economics Literacy Matters for HIV Advocates As an AVAC Clinical Trials Design Academy member and advocate for HIV prevention, developing health economics literacy is vital. It empowers advocates to engage meaningfully in decision-making spaces, to interrogate the value and feasi...
Read more

Highlights from the HIV Cure Pre-Conference at AIDS 2024

By
The 2024 HIV Cure Pre-Conference at AIDS 2024, held today, 21 July 2024, in Munich, was a pivotal event that brought together leading experts and researchers from around the globe to discuss the latest advancements, ongoing challenges, and the future direction of HIV cure research. This pre-conference served as a critical platform for sharing insights into the scientific, structural, and global coordination efforts needed to push forward the ambitious goal of achieving a functional or complete cure for HIV. Keynote Presentation by Deborah Persaud The event began with a powerful keynote address by Dr. Deborah Persaud, who is recognized for her groundbreaking work in pediatric HIV cure research. Dr Persaud provided a comprehensive overview of the current landscape of HIV cure research, particularly focusing on Latency-Reversing Agents (LRAs) in clinical trials. She presented a detailed systematic review that highlighted the need for meticulously designed studies to determine the precise ...
Read more